A detailed analysis in the Canadian Journal of Cardiology of the cost-effectiveness of semaglutide shows that with price reductions, it could meet the benchmark for healthcare value, urging ...

Ozempic, a semaglutide drug originally developed for type-2 diabetes, has been in the news as a fast-track weight-loss ...

FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits. There are differences, however.

CHICAGO — Use of the GLP-1 receptor agonist semaglutide improved walking capability in patients with peripheral arterial disease (PAD) and type 2 diabetes (T2D), regardless of duration of diabetes, ...

A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes ...

Please provide your email address to receive an email when new articles are posted on . Data from SURMOUNT-OSA and a prespecified analysis of the SELECT trial were among the biggest obesity studies in ...

Share on Pinterest A new study finds that GLP-1 drugs’ heart health benefits may not be solely due to weight loss. The Good Brigade/Getty Images As the popularity of GLP-1 receptor agonists for weight ...

WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation ...

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, ...

Patients with type 2 diabetes and a baseline HbA1c greater than 7.0% experienced greater cardiovascular benefits while using oral semaglutide. Oral semaglutide elicits more pronounced cardiovascular ...

BAGSVÆRD, Denmark & PLAINSBORO, N.J., Nov. 10, 2025 /PRNewswire/ -- Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver ...